BioMedNewsBreaks

WednesdayJun 28, 2023 12:21 pm

BioMedNewsBreaks — Ocean Biomedical Inc. (NASDAQ: OCEA) Share Price Target Increased in FRC Report, Receives US Patent for Cancer Immunotherapy Treatment

Ocean Biomedical (NASDAQ: OCEA), a next-generation biopharma company working to accelerate the development and commercialization of compelling new biopharma discoveries, has been spotlighted in a recent Fundamental Research Corp. (“FRC”) report. The equity analyst report increased FRC’s price target of OCEA stock to $17.63 per share, up from its March 2023 of $16.40. According to the report, the uptick was based on several things, including Ocean Biomedical’s $25 million financing facility announced last month; the company being granted two new U.S. patents and one Brazilian patent for drug and vaccine candidates targeting malaria and cancer treatment; positive results from an independent study…

Continue Reading

WednesdayJun 28, 2023 11:33 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Sets Record Date for SRM Entertainment Spin-Off, Share Distribution

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, has announced the record date for the spin-off and distribution of common stock shares, par value $0.0001 per share, of SRM Entertainment Inc. SRM is a majority-owned subsidiary of Jupiter. According to the announcement, the record date is slated for July 7, 2023. On that date, company stockholders and holders of certain warrants will receive one share of SRM common stock, for every 19.35 shares of the company’s common stock held. The announcement noted that fractional shares would be rounded down into whole shares. The company…

Continue Reading

WednesdayJun 28, 2023 11:16 am

BioMedNewsBreaks – iHealthScreen to Host Upcoming Webinar, Report on Fundraising Efforts

iHealthScreen, an artificial intelligence (“AI”)-based health-screening company, has scheduled an exclusive Q&A webinar. CEO Alauddin Bhuiyan will host the event, which is slated for July 11, 2023, at 9 a.m. PDT. During the webinar, Bhuiyan will provide an overview of the company, including how iHealthScreen is disrupting the billion-dollar health screening market; he will also discuss the unique benefits of iHealthScreen's investment opportunity, which capitalizes on the company’s proprietary AI-driven, health-screening software. According to the announcement, iHealthScreen is one of the first companies in the world to receive CE certification and Australian and UAE health approvals for the screening of…

Continue Reading

TuesdayJun 27, 2023 2:49 pm

BioMedNewsBreaks — Ocean Biomedical Inc. (NASDAQ: OCEA) Cofounder Issued Key US Patent for Bispecific Cancer Immunotherapy Treatment

Ocean Biomedical (NASDAQ: OCEA) is reporting that a broad U.S. patent has been issued to Dr. Jack A. Elias, MD, one of the company’s scientific cofounders. The patent is for bispecific antibodies targeting chitinase 3-like-1 (“CHi3L1”) and programmed cell death protein 1 (“PD-1”). The company called it “a promising new approach that has emerged from prior breakthrough discoveries that CHi3L1 is a ‘master regulator’ of tumor growth in multiple visceral cancers.” According to the announcement, the bispecific antibody is a cutting-edge immunotherapy approach that demonstrates significant potential by combining Ocean’s proprietary anti-CHi3L1 antibody with existing immune checkpoint inhibitors that target PD-1…

Continue Reading

TuesdayJun 27, 2023 11:03 am

BioMedNewsBreaks – iHealthScreen Announces Successful Fundraising Efforts, Reaches $150K on StartEngine

iHealthScreen, an artificial intelligence (“AI”)-based health-screening company, announced that it has raised $150,000 on StartEngine. An AI-driven, HIPAA-compliant medtech company, iHealthScreen uses AI to screen for retinal diseases, stroke and heart disease and prevent blindness, deaths and disabilities. In addition to the $150,000 raised on StartEngine, iHealthScreen has raised more than $3 million in seed and NIH funding. The company offers investors a unique opportunity to capitalize on AI-driven, health-screening software developed by medical professionals. According to the company, testing for certain diseases and conditions can be cost prohibitive, and primary care providers often don't have resources to do more…

Continue Reading

MondayJun 26, 2023 3:41 pm

BioMedNewsBreaks – MoonLake Immunotherapeutics’ (NASDAQ: MLTX) Shares See Significant Increase Based on Success of IL-17 Nanobody Phase 2 Trial

MoonLake (NASDAQ: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, has announced positive top-line results from its global phase 2 MIRA trial. The trial (“M1095-HS-201”) evaluated the efficacy and safety of the Nanobody(R) Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (“HS”). MoonLake’s shares closed nearly $20.00 up on the day to $45.95 following the recent news. “As part of our efforts to elevate outcomes for patients, we set an ambitious goal for our Nanobody(R) Sonelokimab to ‘meet or beat’ the best results shown in pivotal-like trials of competitors,” said Jorge Santos da Silva, PhD, founder…

Continue Reading

MondayJun 26, 2023 3:02 pm

BioMedNewsBreaks – NextPlat Corp. (NASDAQ: NXPL) Now Included in Russell Microcap(R) Index

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, is joining the Russell Microcap(R) Index, effective today. The company announced that it will be included following the conclusion of the 2023 Russell indexes annual reconstitution. According to the announcement, Russell Microcap Index membership is in effective for one year and consists of automatic inclusion in the appropriate growth and value style indexes. The announcement observed that objective, market-capitalization rankings as well as style attributes are primarily used by FTSE Russell to determine membership of index members. “NextPlat's inclusion in the Russell Microcap Index is important recognition of the value of our global…

Continue Reading

FridayJun 23, 2023 2:26 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Working to Deliver Novel Treatment for Chronic Pain Sufferers

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, recently announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia and other chronic pain conditions. Silo intends to leverage its existing partnerships with academic research institutions to help move the novel treatment for chronic pain sufferers through the Food and Drug Administration’s approval process as efficiently as possible. The fibromyalgia market grew to $3.1 billion last year and is expected to continue increasing at a compound annual growth rate of 4% over the next decade. Meanwhile,…

Continue Reading

FridayJun 23, 2023 12:12 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, was featured in a video published by InvestmentPitch Media. FSD Pharma recently entered into a non-binding letter of intent with 1319741 B.C. Ltd., an unlisted reporting issuer, which will be renamed Celly Nutrition Inc. FSD Pharma and Celly Nutrition (“Celly Nu”) intend to enter into a definitive licensing and loan agreement whereby FSD will provide Celly Nu an exclusive license to commercialize products developed using FSD’s IP for alcohol misuse…

Continue Reading

ThursdayJun 22, 2023 11:46 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) 755-201-EB Trial Demonstrates Clinically Important Results

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced safety and efficacy results from its phase 2 clinical trial. The purpose of the trial, called “755-201-EB,” was to evaluate the safety of INM-755 CBN cream, which consists of the control cream plus the active pharmaceutical ingredient CBN, and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with epidermolysis bullosa (“EB”). According to the announcement, of the 18 participants assessed, chronic itch improved by a clinically meaningful amount in…

Continue Reading